Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals and keeping the price target at $5.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy’s rating is based on Actinium Pharmaceuticals’ promising developments in targeted radiotherapies, particularly with their ATNM-400 program. The company has demonstrated encouraging preclinical results in various cancer models, including lung, prostate, and now breast cancer, which could potentially lead to significant clinical opportunities.
Additionally, Actinium’s financial position is strong, with a cash runway extending into 2028, allowing them to continue advancing their pipeline without immediate financial pressure. The upcoming presentation of preclinical data at the San Antonio Breast Cancer Symposium is expected to further highlight the potential of ATNM-400, capturing investor interest and supporting the Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Neuphoria Therapeutics, and Medicus Pharma Ltd. According to TipRanks, McCarthy has an average return of -19.0% and a 29.78% success rate on recommended stocks.
In another report released on November 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.